PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Olaparib

Drugs in development · updated 30 October 2026

Olaparib: clinical trials and development status

Other names and codes: AZD2281, Lynparza

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 16 December 2014

As of 30 October 2026 Olaparib is in 178 active clinical trials (recruiting or ongoing, phases I–III) for 70 diseases. The most advanced phase is III.

178Active trials
IIIMost advanced phase
70Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Olaparib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 70 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmIII36NCT06112379
Ovarian neoplasmIII34NCT06915025
Fallopian tube neoplasmIII17NCT06915025
Triple-negative breast neoplasmIII17NCT06966700
Endometrial neoplasmIII8NCT04269200
NeoplasmIII8NCT06580314
Lung small cell carcinomaIII6NCT04624204
Lung neoplasmIII5NCT04380636
Non-small-cell lung carcinomaIII5NCT04380636
Ovarian epithelial carcinomaIII3NCT06915025
Hematologic neoplasmIII1NCT03486873
MetastasisII13NCT05564377
Prostatic NeoplasmsII10NCT04038502
Pancreatic neoplasmII9NCT05093231
GlioblastomaII5NCT02974621
GliomaII5NCT03212274
CholangiocarcinomaII4NCT03212274
Head and neck squamous cell carcinomaII3NCT04643379
Neuroendocrine tumorI–II3NCT04086485
Non-Hodgkin lymphomaII3NCT02693535
OsteosarcomaII3NCT04417062
Renal cell carcinomaII3NCT03741426
Stomach neoplasmI–II3NCT02734004
Bladder neoplasmII2NCT03459846
Carcinoma, EndometrioidII2NCT03660826
CarcinosarcomaII2NCT03660826
EpendymomaII2NCT03155620
MedulloblastomaII2NCT03155620
Multiple myelomaII2NCT02693535
NeuroblastomaII2NCT03155620

Everything on Olaparib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch